acurxpharma.com - נכסים נקיים למניה בודדת ACXP

Acurx Pharmaceuticals (ACXP) demonstrates potential through the development of innovative treatments against resistant bacteria. The book value per common share visualizes capital dynamics, where 1.74 forms the current metric value. The model relies on low production costs coupled with high patent leverage. Management's lean approach to research is aimed at securing major strategic partners.

Book value per share reflects the portion of net assets attributable to a single security, allowing for an assessment of the real value of capital net of liabilities. By analyzing the book value per share chart, an investor can track the trend of dilution or consolidation of stakes, which is critical for Acurx Pharmaceuticals (ACXP), as its antibiotic development costs—subject to economic standards—directly impact residual capital.